A detailed history of China Universal Asset Management Co., Ltd. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 139,352 shares of SMMT stock, worth $2.64 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
139,352
Previous 82,473 68.97%
Holding current value
$2.64 Million
Previous $643,000 374.49%
% of portfolio
0.34%
Previous 0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$6.89 - $31.93 $391,896 - $1.82 Million
56,879 Added 68.97%
139,352 $3.05 Million
Q2 2024

Jul 19, 2024

SELL
$2.39 - $10.92 $125,169 - $571,902
-52,372 Reduced 38.84%
82,473 $643,000
Q1 2024

Apr 29, 2024

BUY
$2.55 - $5.07 $137,123 - $272,634
53,774 Added 66.33%
134,845 $558,000
Q4 2023

May 21, 2024

SELL
$1.67 - $2.83 $89,802 - $152,180
-53,774 Reduced 39.88%
81,071 $211,000
Q4 2023

Jan 23, 2024

BUY
$1.67 - $2.83 $105,490 - $178,765
63,168 Added 352.83%
81,071 $212,000
Q3 2023

May 21, 2024

BUY
$1.54 - $2.42 $13,487 - $21,194
8,758 Added 95.77%
17,903 $33,000
Q3 2023

Oct 30, 2023

BUY
$1.54 - $2.42 $13,487 - $21,194
8,758 Added 95.77%
17,903 $33,000
Q2 2023

May 21, 2024

SELL
$1.32 - $2.81 $406 - $865
-308 Reduced 3.26%
9,145 $22,000
Q2 2023

Jul 27, 2023

SELL
$1.32 - $2.81 $406 - $865
-308 Reduced 3.26%
9,145 $23,000
Q1 2023

May 21, 2024

BUY
$1.38 - $5.41 $10,223 - $40,077
7,408 Added 362.25%
9,453 $16,000
Q1 2023

Apr 27, 2023

BUY
$1.38 - $5.41 $10,223 - $40,077
7,408 Added 362.25%
9,453 $17,000
Q4 2022

May 21, 2024

SELL
$0.68 - $5.31 $90,304 - $705,168
-132,800 Reduced 98.48%
2,045 $8,000
Q4 2022

Jan 31, 2023

BUY
$0.68 - $5.31 $108 - $849
160 Added 8.49%
2,045 $9,000
Q3 2022

Oct 21, 2022

BUY
$0.89 - $1.63 $1,677 - $3,072
1,885 New
1,885 $2,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.82B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.